Most mental illnesses emerge during adolescence and early adulthood, with considerable associated distress and functional decline appearing during this critical developmental phase. Our current diagnostic system lacks therapeutic validity, particularly for the early stages of mental disorders when symptoms are still emerging and intensifying and have not yet stabilized sufficiently to fit the existing syndromal criteria. While this is, in part, due to the difficulty of distinguishing transient developmental or normative changes from the early symptoms of persistent and disabling mental illness, these factors have contributed to a growing movement for the reform of our current diagnostic system to more adequately inform the choice of therapeutic strategy, particularly in the early stages of a mental illness. The clinical staging model, which defines not only the extent of progression of a disorder at a particular point in time but also where a person lies currently along the continuum of the course of an illness, is particularly useful as it differentiates early, milder clinical phenomena from those that accompany illness progression and chronicity. This will not only enable clinicians to select treatments relevant to earlier stages of an illness, where such interventions are likely to be more effective and less harmful than treatments delivered later in the course of illness, but also allow a more efficient integration of our rapidly expanding knowledge of the biological, social, and psychological vulnerability factors involved in the development of mental illness into a useful diagnostic framework.
Can J Psychiatry. 2010;55 (8) : 486-497. benign and self-limiting states and states that represent the early stages of what will become persistent and disabling conditions. 7 While much distress seems, initially at least, selflimiting, 5 it is important not to trivialize the significance of this as subthreshold symptoms strongly predict future disorder. 6, [8] [9] [10] [11] The concepts and definitions we have used to date, while they are syndromal and descriptive, tend to be circular and lack discriminant validity and therapeutic utility. Technical solutions such as hierarchies initially obscured the problem; however, currently popular dimensional adjuncts are just as unlikely to solve it. There is an overdue impatience with the traditional so-called purer categories and a welcome desire to explore larger superordinate categories with a complementary dimensional cross-cutting matrix. 12 However, no practical research strategy has yet been formulated to take us beyond the current impasse. What is required is a heuristic strategy that aims to develop ground rules for clarifying, as early as possible, which people with emotional and behavioural disturbance are at particular risk of persistent and disabling mental illness, and what the sequence of established and novel or experimental therapeutic strategies is most likely to not only successfully achieve remission of current symptoms and psychosocial recovery but also to reduce the risk of persistence and recurrence.
We have been very patient with the traditional diagnostic system, which, for the psychotic and mood disorders, is over a century old. Having struggled with Procrustean diagnostic concepts that receive little validation until the illness has fully evolved, we are now beginning to see how a more flexible system linking the course, extension, and pattern of illness over time may be more strategically useful, not only in clinical practice but also in basic research. Our current diagnostic systems are characterized by artificial divisions based on cross-sectional symptom sets, propped up with course and outcome variables. Early clinical features are not differentiated from those that become apparent as a disorder persists, and no consideration is given to the definition of the onset of a disorder. The traditional diagnostic concepts in the mood and psychotic disorders have been derived from the more prevalent subsamples of chronic patients, thereby enhancing the impression of stability and validity. However, in everyday clinical practice, operationally defined diagnostic criteria have unfortunately done little more than create a spurious precision that does not extend far beyond the research setting, and questions of validity and utility remain unresolved. 12, 13 They may be alternately viewed as stable outcome variables, rather than useful tools for guiding early intervention or treatment of people with less severe illness, or as uncovering underlying pathological mechanisms.
The ubiquity of comorbidity and polypharmacy provides evidence of the practical weakness of our current diagnostic concepts. Drug therapies lack specificity for individual diagnoses as reflected in high levels of off-label use and ever-widening indications. Psychosocial treatments appropriately focus on broader personal and social needs and hence range freely across the diagnostic landscape. How can we reform and refine diagnosis so that treatments can be selected in a safer, more effective manner, prognosis can be more accurately assessed, and the confusing array of biological disturbances rearranged into something resembling a clinicopathological framework? Clinical staging, a deceptively simple and practical tool found useful in other areas of medicine, may provide a way forward. 14, 15 In a preemptive psychiatry based on the clinical staging paradigm, end-stage syndromes such as deficit schizophrenia may fade into the background as destinations to be avoided. This is a welcome departure from the deterministic thinking that has plagued psychiatry for so long, and opens the door for better understanding of gene-environment interactions in the onset and course of psychiatric illness. 16 
What Is Clinical Staging?
Clinical staging is, simply, a more refined form of diagnosis. Its value is recognized in the treatment of malignancies and many other potentially serious medical illnesses, such as diabetes and arthritis, where limiting the extension and secondary impacts of the disease, and improving quality of life and survival, all rely on the earliest possible delivery of effective interventions. Clinical staging differs from conventional diagnostic practice in that it defines not only the extent of progression of a disorder at a particular point in time but also where a person lies currently along the continuum of the course of an illness. The differentiation of early and milder clinical phenomena from those that accompany illness extension, progression, and chronicity, lies at the heart of the concept, which therefore makes it especially useful in adolescence and early adulthood, when most adult-type disorders emerge for the first time. A staging framework enables clinicians to select treatments relevant to earlier stages of an illness, and generally assumes that such interventions will be both more effective and less harmful than treatments delivered later in the course.
Early successful treatment may change the original prognosis and thus prevent progression to subsequent stages, optimally resulting in remission and cure. Our current diagnostic categories are disconnected from the underlying substrates of the disorders and impose artificial boundaries without clinical utility. In addition to guiding treatment selection, a staging framework, which cuts across the current diagnostic silos to encompass a broader range of clinical phenotypes, yet which introduces subtypes along a longitudinal dimension, has the potential to organize endophenotypic and biomarker data in a more coherent and mutually validating fashion.
How Do We Define the Stages of a Disorder?
In other medical conditions, clinical stages are defined by the extent and progression of the illness and its biological impact on the patient, which, in turn, must correlate with prognosis. This approach usually depends on a capacity to define pathologically, as well as clinically, the limits or extent of the disease process. In clinical psychiatry, this could involve not only a cross-sectional clinical definition but also a wider biopsychosocial definition of extent or progression. Therefore, in addition to the severity, persistence, and recurrence of symptoms, biological changes (for example, hippocampal volume loss, neurocognitive deficits, and dysregulation of the HPA axis) and the social impact of a disorder (for example, the effect on social relationships and employment) could also be drawn into the definition. Ultimately, something approaching a clinicopathological model could emerge. Table 1 gives an initial flavour of how such a heuristic model could be formulated, with a focus on the domain of psychotic and mood disorders. Other syndromal domains could be addressed in parallel or incorporated subsequently.
What Are the Potential Benefits of Staging?
On the clinical side, defining discrete stages according to progression of disease creates a framework for the evaluation of interventions oriented toward prevention and cure. The aim is to prevent progression to more advanced stages, or to promote regression to an earlier stage, including full and sustained remission. To achieve this, an accurate understanding of the social, biological, and personal risk and protective factors that influence progression from one stage to the next will be essential. Further, we need to know the relative potency of these risk factors and which may be responsive to current interventions. While some factors may operate across several or all stage transitions, others may be stage-specific; for example, substance misuse or stress may be especially harmful in triggering the onset of the first episode of an illness, yet be less toxic subsequently (or vice versa). Geneenvironment interactions almost certainly underpin and mediate these transitions, where environmental variables, such as substance misuse, psychosocial stressors, cognitive style, medication adherence, and social isolation, may interact with genetic and other biological risk factors. Recent advances in the understanding of epigenetics and brain plasticity offer new pathways to influencing such transitions.
A clinicopathological staging model that spans the current diagnostic categories and allows the mapping of the relations between biological markers and the stages of disorder will allow us to define and validate more meaningful boundaries for clinical entities, and distinguish core biological processes from epiphenomena and sequelae, enabling existing knowledge to be better represented and understood. 12 It is likely that by focusing earlier on what appear to be pluripotential syndromes, and testing broader psychosocial and more generic neuroprotective interventions, we may learn more about the subtle pathophysiology of the onset and persistence of disorder and distinguish this better from vulnerability, on the one hand, and sequelae on the other. 
The Pluripotential Risk Syndrome, Compared With the Specific Prodrome
The above discussion points to several questions regarding the specificity of the earliest stages of psychiatric disorders. First, if we define target syndromes such as deficit schizophrenia, persistent or recurrent major depression, or fully developed mania, how soon can specific indicators of progress toward such defined syndromes or disorders be recognized? A second, related question is whether earlier stages of disorders, which tend to be phenotypically very similar, are in fact pluripotential (that is, may develop into one of a range of disorders) or whether they contain a so-called mixed bag of people on the way to a fixed destination, a particular target or outcome, such as schizophrenia (that is, a predetermined outcome). If we follow prospective cohorts, we may see a gradual separation and intensification over time within individual patients of symptom clusters and syndromes, often in a kaleidoscopic fashion ( Figure 1 ). An apparently pluripotential prodrome may exit into psychotic disorders, nonpsychotic mood and anxiety disorders, SUDs, or comorbid combinations of these disorders.
Can these alternative models, pluripotentiality compared with predetermination, of the evolution of psychiatric disorders be distinguished? The question can be addressed by naturalistic studies to some extent, but ultimately RCTs of different interventions and measurement of potentially predictive biomarkers and risk factors may be more informative in revealing to what extent the clinical pathways are fluid or fixed.
Staging and Psychosis: A Framework for Preventively Oriented Care
During the past 15 years, a systematic international collaborative movement of clinicians and researchers has sought to modify and apply the principles and practice of early diagnosis and staged treatment to psychotic disorders. [17] [18] [19] [20] A key rationale for early intervention has been the relation between prolonged illness duration and poor outcome in the psychotic disorders. 21, 22 In a recent meta-analysis 23 and systematic review, 22 longer DUP was associated with poorer response to antipsychotic treatment as measured by severity of global psychopathology, positive and negative symptoms, demoralization, depression, and functional outcomes. Neuroimaging studies 24 have also indicated that prolonged untreated illness is associated with more pronounced structural brain abnormalities, while this is less prominent earlier in the course of the disorder. Treatment delay may be reduced by early detection and intervention, resulting in improved short-and longerterm outcome. [25] [26] [27] [28] RCTs have also suggested that initiation of atypical antipsychotic therapy at FEP may prevent progression of the structural changes seen in the disorder. 29
The Prodromal or UHR Stage
Initially, the early psychosis movement focused on the timely recognition and phase-specific treatment of FEP. However, it was also recognized that for most patients a prolonged period of attenuated symptoms and impaired functioning precedes FEP. 30, 31 Much of the disability associated with the psychotic disorders, particularly schizophrenia, develops long before the onset of frank psychosis and is difficult to reverse even if FEP is successfully treated. 32 This pre-onset period of illness has been termed the prodromal phase. 33, 34 Within the context of the early intervention paradigm, researchers suspected that pushing the point of intervention even further back from FEP to the prodromal phase may result in even better outcomes. 35, 36 Intervening during this phase may ameliorate, delay, or even prevent onset of full-fledged disorder, 11 thereby reducing the burden of disability, prevalence, and possibly even the incidence of psychotic disorders.
However, this goal presented the major challenge of prospectively identifying the prodromal phase, a task complicated by the nonspecific nature of prodromal symptoms. 37 Criteria were introduced for the prospective identification of people at heightened risk of developing FEP within a brief time period-that is, as possibly in the prodromal phase of illness. These criteria are based on a combination of known trait and state risk factors for psychosis, including attenuated positive psychotic symptoms, brief self-limited psychotic symptoms, and family history of psychotic disorder. They have been termed the UHR criteria. 38 The first published study 38 using the UHR criteria found a transition rate of 40% to fullthreshold psychotic disorder within 1 year, despite the provision of needs-based psychosocial intervention and antidepressant treatment where indicated. This finding has subsequently been replicated by several groups internationally, [39] [40] [41] including the recent multicentre North American Prodromal Longitudinal Study. 42, 43 Using a combination of studies, Ruhrmann et al 44 reported an average 1-year transition rate of 36.7% in UHR subjects who did not receive antipsychotic treatment. These results indicated that the UHR criteria are valid and reliable criteria for predicting psychosis onset in this population.
Intervention Studies in UHR Groups
The successful identification of the at-risk population facilitated 2 important advances in the early psychosis field: research into processes associated with the onset of psychosis, including psychopathological, neurocognitive, and neurobiological variables; and the implementation of intervention trials aimed at treating existing symptomatic and functional impairment in the UHR population and determining whether specific interventions are able to ameliorate, delay, or prevent onset of full-fledged psychotic disorder in this population.
The intervention studies to date are summarized briefly below (see McGorry et al 45 for a review). The first such intervention trial, conducted by McGorry et al 46 in Melbourne, Australia, compared combined CBT and low-dose atypical antipsychotic medication (risperidone) (n = 31) with usual case management (n = 28). Subjects were randomized, but neither patients nor investigators were blind to the intervention received. The rate of psychosis onset in the treatment group was significantly lower than in the control group at the end of the 6-month treatment phase (9.7% and 35%, P = 0.03). However, after a further 6 months of follow-up, this finding was no longer statistically significant, owing to patients who were not fully adherent to their antipsychotic medication developing psychotic disorder during the second 6-month period. Patients who were fully adherent to risperidone during the initial 6-month treatment phase all remained nonpsychotic during the follow-up period, even though they had ceased drug treatment. This study 46 demonstrated that the onset of psychosis can at least be delayed, if not prevented, by specific intervention. However, the active component of the treatment regime could not be identified as medication and CBT were combined. The results also suggested that further benefit may be obtained with a longer treatment time, an outcome reinforced by a longer-term follow-up of the sample, which failed to show any persisting benefit during 3 to 4 years in the experimental group. 47 A more sophisticated double-blind placebo-controlled RCT was then conducted by researchers from Yale University. 48 Low-dose olanzapine (n = 31) was compared with placebo (n = 29) for 12 months followed by a 12-month monitoring period. Although there was a trend toward the olanzapine-treated group having a reduced rate of transition to psychosis, this finding was not significant. There were also some adverse effects associated with olanzapine treatment, leading to a more conservative interpretation of the results. 49 The risk-benefit ratio for olanzapine thus appears to be less favourable than risperidone at this stage of illness.
A third RCT in UHR patients was conducted in Manchester, England. 50 Subjects (n = 58) were randomized to receive CBT for 6 months or monitoring of mental state only. The group that received CBT had a significantly lower rate of transition to full-threshold disorder (6% and 26%, P < 0.05) and a significantly greater reduction in psychiatric symptoms (P < 0.02) at 12 months. At 3-year follow-up, CBT was associated with a significantly lower rate of transition to psychosis when baseline cognitive factors were controlled for and a significantly reduced likelihood of being prescribed antipsychotic medication. Consistent with this, Bechdolf et al 51 reported that for patients in the early initial prodromal state, as identified by the presence of basic symptoms, CBT was superior to supportive counselling in reducing progression to subthreshold psychotic symptoms and to full-threshold psychosis during 24 months. An intensive early intervention program (the Danish OPUS trial 52 ) also indicated that transition rates could be reduced in a group of patients with schizotypal disorder by intervening with the OPUS package, which consisted of intensive clinical case management, family involvement, and a psychoeducational approach within a CBT framework.
Recently, there has been interest in the possibility of using antidepressants to reduce risk of psychosis in high-risk samples. Cornblatt et al 53 reported a naturalistic study of young people with prodromal symptoms treated either with antidepressants or antipsychotics. Twelve of the 28 patients (43%) who had been prescribed antipsychotics progressed to full-threshold psychosis in the following 2 years, whereas none of the 20 patients treated with antidepressants subsequently developed psychosis. Similar results are reported by Fusar-Poli et al 54 based on a file audit. However, these results need to be interpreted with caution, owing to the uncontrolled nature of the studies: there may have been differences in baseline symptom, functioning, or other variables between treatment groups, and nonadherence was far more prominent among patients prescribed antipsychotics than patients prescribed antidepressants. Our initial trial 46 found that antidepressants, again prescribed according to clinical need, had no influence on the transition rate.
Open-label trials of aripiprazole and the amino acid glycine have also recently been conducted in the UHR population. In the aripiprazole trial, 55 UHR patients (n = 15) were treated with a flexible dose regime of 5 to 30 mg/day for 8 weeks. Improvements on clinical measures were evident by the first week and no participants transitioned to psychosis. Adverse events were minimal. These findings indicate a promising efficacy and safety profile for aripiprazole for UHR patients.
In the glycine pilot trial, 56 UHR patients (n = 10) were treated with glycine during an 8-week period. No participants transitioned to full-threshold psychosis and significant improvements in different psychopathological domains were reported, with minimal side-effects.
In a recent, more sophisticated double-blind placebocontrolled RCT, Phillips et al 57 compared the combinations of risperidone and CBT with placebo, and CBT or placebo and supportive therapy, in a group of UHR patients (n = 115). The 6-month transition rates were low in all 3 treatment groups, suggesting that antipsychotics may not be necessary in UHR patients who are detected early, or that recent UHR cohorts are derived from less so-called enriched samples for the true positive rate. 58, 59 Early detection and treatment may mean that more benign interventions are sufficient at this stage of illness. These should certainly be offered first; only when symptoms and impairment persist or worsen should other options such as drug therapies be considered. Further, the high rates of psychoticlike experiences in community cohorts 60, 61 is consistent with the notion that a staged approach to treatment may be indicated, with antipsychotic agents not necessary for all people with subthreshold psychotic symptoms.
Another recent study 62 lends further support to this staged approach to intervention in the UHR group. This was a 12-week placebo-controlled RCT of the omega-3 fatty acid EPA in a group of UHR adolescents (n = 80). At the end of the 12-week intervention phase, 8 of 38 (21.1%) people in the placebo group and 1 of 38 (2.6%) in the EPA group had progressed to FEP, a statistically significant difference (P = 0.03). No clinically significant adverse effects were reported, and EPA was well accepted by this patient group. Most notably, the treatment effect was maintained at 6-month follow-up. 62 Previous treatment studies of EPA supplementation in different samples of psychotic patients indicate that the effect of EPA is dependent on stage of illness. EPA has been found to be partially effective in samples with recent onset psychosis 63, 64 but have no effect in chronic schizophrenia. 65 These findings support the clinical staging model in that the effect of the intervention seems dependent on the stage of illness progression. There is also good evidence that EPA has a generalized positive effect on mental health complaints. 66, 67 This generalized effect is appropriate for the UHR group, who have been found to have a wide variety of general psychiatric features, not only attenuated psychotic symptoms, and which are a target in their own right. 57 Applying the clinical staging model to treatment of the UHR population, the evidence reviewed above indicates that so-called gentler therapies such as EPA or psychosocial interventions, including CBT or supportive therapy, may be suitable as a first-line treatment in UHR patients. However, the clinical staging model does not necessarily mean eschewing study of the role of antipsychotic medication in this population. Broad spectrum antipsychotics may also have a neuroprotective effect, reduce anxiety and depression, and may possess minimal side effects. They may still have a place in delaying or preventing psychosis onset and should be further studied, especially in people who present late with UHR symptoms or fail to respond to initial intervention with gentler therapies. The best candidates are those with a more favourable metabolic and neurological safety profile, such as quetiapine and aripiprazole. 68 It is also possible that optimal treatment is not determined solely by stage-of-illness factors (that is, whether the patient is high risk, the degree of high risk, or whether he or she is suffering from FEP or in a chronic stage of illness). In other words, symptom severity alone, as we have defined it in the definition of transition, may not be a perfect guide for the need for antipsychotic medication. There may be other factors, such as symptom type and other clinical phenomena, comorbid SUDs, triggers and stressors, genetic and other biomarkers, that could determine optimal treatment for a given patient. Therefore, some UHR patients may benefit from treatment with antipsychotics, while some FEP patients, especially those with a very short DUP, may not and may remit with intensive psychosocial interventions. Further intervention research is required to shed light on these issues.
Reduced Transition Rate-What Are the Implications?
Another critical finding in the UHR group is that the transition rate to full-threshold psychosis has been dropping in recent cohorts. At the Personal Assessment and Clinical Evaluation Clinic in Melbourne the transition rate has dropped from about 50% in 1995 to about 12% in 2000, with each successive year showing a transition rate of 0.80 times that of the preceding year. 59 There has also been a shorter duration of symptoms before entering the clinic for more recent cohorts.
A similarly reducing transition rate has been observed in other UHR clinics. The reasons for the reducing transition rate are unclear. It may be due to earlier detection and treatment of UHR samples, allowing psychosocial intervention to be more effective in delaying or reducing transition, in line with the staging model. It may also be due to identifying more false positives in UHR samples (that is, a diluted sample with less inherent risk), owing to different referral patterns. Alternatively, as patients now have a much shorter duration of prodromal symptoms, it may be an example of lead time bias where the patients need to be followed for a longer period before we can say that the transition rate and level of risk have truly been reduced. We are currently conducting a long-term follow-up study that may help to clarify these possibilities. The lower transition rates and consequently higher falsepositive rates (at least in short-term follow-up) mean that safer interventions must be offered as the first-line treatment for people who nevertheless have a clear-cut need for care of some kind. Conceptually, this is consistent with the clinical staging model.
Interventions for FEP
FEP can be divided into the period before psychosis is detected and the period after detection. Unfortunately, the undetected-untreated phase can be prolonged, even in developed countries. 69 Even when psychosis is detected, the initiation of effective treatment may still be delayed. Postdetection, the intervention goals are engagement and the initiation of pharmaceutical and psychosocial treatments.
Intensive interventions aimed at maximal symptomatic and functional recovery and the prevention of relapse are ideally delivered during the early weeks and months of treatment.
The controversy surrounding the importance of DUP and treatment delay in FEP seems to have been largely resolved following the publication of some key systematic reviews 22, 23 and recent influential longitudinal research. These studies have now established that longer DUP is both a marker and an independent risk factor for poor outcome. The Early Treatment and Intervention in Psychosis study in Scandinavia has shown, through an innovative study design, that reducing DUP leads to early benefits in reducing suicidal risk and severity of illness at initial treatment, and sustained benefits for negative symptoms and social functioning. 70 The relation between DUP and outcome is robust, sustained over many years of follow-up, 71, 72 and is also found in low-and middle-income countries. 73 However, these studies show that, though it is a malleable risk factor, DUP accounts for a relatively modest amount of outcome variance, underlining the importance of treatment access, retention, and quality during the early years of illness.
There is an extensive literature attesting to the benefits of comprehensive care of FEP, which has been summarized in the International Clinical Practice Guidelines for Early Psychosis published in 2005. 74 Since then, the large multicentre EUFEST study 68 has shown that in the treatment of first-episode schizophreniform and schizophrenic disorders, atypical or second-generation antipsychotics have some clear-cut advantages. While most patients responded well to both typical and atypical medications, with no significant differences in efficacy, the discontinuation rate and tolerability were clearly superior for the atypical agents. This was true even when contrasted with very low-dose haloperidol. While the authors' conclusions and recommendations were conservative, highlighting the equivalent efficacy of both drug classes, the EUFEST findings contrast markedly with those of the Clinical Antipsychotic Trials of Intervention Effectiveness (commonly known as CATIE) study in chronic schizophrenia where no dramatic advantages were found for atypicals using similar primary outcome measures. The EUFEST data support the recommendations in the International Clinical Practice Guidelines for Early Psychosis, which favour the use of the atypicals as first-line therapy, owing to their better tolerability (a crucial issue in drug-naive FEP patients) and the reduced risk of tardive dyskinesia. 68, 74 However, certain atypicals are associated with a particularly high risk of significant weight gain and metabolic problems, and these risks need to be carefully managed and prevented wherever possible. 75 Psychosocial treatments in early psychosis have been extensively studied, with positive findings pointing to the value of cognitive therapies in accelerating and maximizing symptomatic and functional recovery. 76 Increasingly, there has been attention to medications because-although assisting in symptomatic recovery-they do not contribute to a return to functioning. This has led to an increased focus on the need to enhance social recovery, 77 especially educational and vocational aspects, [78] [79] [80] through the combination of effective psychosocial interventions with well-managed medication. There is also an increasing focus on targeted cognitive remediation and on limiting the degree of cognitive decline that is often found as illness progresses. 81, 82 
Next Steps in FEP Intervention
The place of the new injectables and clozapine needs to be clarified as well as that of adjunctive neuroprotective agents, such as omega-3, lithium, and N-acetyl cysteine. 62, 63, 83, 84 With the advent of very short DUP for many patients, there may be a subset of FEP patients for whom intensive psychosocial intervention may be sufficient as a first-line treatment approach without initial antipsychotic medication. We are currently conducting an intervention study to examine this possibility. CBT, family intervention, targeting of substance abuse, suicide risk, and vocational rehabilitation are the key psychosocial interventions in early psychosis and need to be much more intensively and widely deployed. 17, [85] [86] [87] [88] Assertive community treatment for the subset of poorly engaged patients is vital. Family interventions are also an essential element of care. They have been shown to lead to shorter periods of hospitalizations in FEP patients, assisting parents in supporting their children within the community. 89 A family psychosocial module was also an essential component in a relapse prevention intervention that was more effective than standard care at preventing the occurrence of a second episode of psychosis. 90 In patients with schizophrenia, the evidence indicates that the relapse rate can be reduced by 20% if relatives are included in treatment. 91
The Critical Period After Diagnosis and Treatment of FEP
The years beyond FEP have been referred to as the critical period. 92 Treatment goals in this phase are sustained engagement and tenure in specialized care, continuing effective medication management and the use of effective psychosocial interventions to minimize the risk of relapse and the development of disability, and to maximize social and functional recovery. Proof of concept is now established for these strategies, at least in the short term. 90, [93] [94] [95] However, there remains a large gap in most communities between what works and what is available, even in high-income countries, and certainly in low-and middle-income countries. 96 Beyond FEP, we know that the first 2 to 5 years postdiagnosis are crucial in setting the parameters for longer-term recovery and outcome. This is the period of maximum risk for disengagement, relapse, and suicide, as well as coinciding with the major developmental challenges of forming a stable identity, peer network, vocational training, and intimate relationships. It makes sense that a stream of care specially focused on young people and on this stage of illness is required to maximize the chances of engagement, continuity of care, appropriate lifestyle changes, adherence to treatment, family support, and vocational recovery and progress. Indeed, the available evidence from naturalistic and randomized studies strongly supports the value of specialized early psychosis programs in improving outcome in the short term. If these programs are only provided for 1 to 2 years, there is also evidence that some of the gains are eroded, suggesting that, for a substantial subset at least, specialized early psychosis care needs to be provided for a longer period, probably up to 5 years for many patients. 72, 85, 93 At this point persisting illness and disability may be present in a much smaller percentage of people whose needs may subsequently be well met by more traditional mental health services for older adults. This may be a much better point to transfer care.
Risk Syndromes, Staging, and Early Intervention for Mood Disorders
Having pushed the target for early intervention in psychotic disorders to extend to the prodromal phase, a key question to now ask is: Can we treat even earlier? [97] [98] [99] [100] [101] [102] [103] Further, the UHR criteria described above, which were defined with the prediction of nonaffective psychosis in mind, lead to a heterogeneous range of diagnoses across the spectrum of psychosis, including psychotic depression and mania. 38 Before the onset of attenuated psychotic features, in the early prodrome of schizophrenia, general symptoms such as irritability, anxiety, and depression are known to occur, which could evolve into numerous different clinical outcomes (as well as resolve). 104 Häfner et al 105 failed to distinguish the prodromal stage of schizophrenia from that of depression in a retrospective study. Thus the challenge here is to determine if different end-stage syndromes (such as schizophrenia, BD, and unipolar depression) have a common pluripotential early onset phase, or whether there is any early specificity of the clinical phenotype. More work is required to clarify whether there is a specific prodromal stage for mood disorders that can be reliably differentiated from the prodrome of psychotic disorders. This would justify specific early identification and intervention strategies for mood disorders. The alternative approach is to have a broader risk-identification and intervention approach, consistent with the pluripotential model.
Fava and Tossani 106 reviewed the literature for identifying a prodrome for depressive disorders. They concluded that anxiety and irritability are commonly observed in the prodromal phase of depression; that subthreshold or minor depression is implicated as a risk factor for the development of major depression, reinforcing the notion that depressive symptoms occur on a continuum rather than in discrete categories; and that prodromal symptoms can persist after full-threshold episodes as residual symptoms, which may inform efforts toward relapse prevention. 107 Subsyndromal depression is significant, not only as a risk factor for depressive disorders but also because of its high prevalence and the impact of symptoms on functioning. 108 Eaton et al 6 highlighted the greatly increased risk of major depression conferred by subthreshold depressive symptoms, thus laying the foundations for intervention studies to reduce this risk. To date, few have taken up this challenge. However, although including some mixed results, studies by Jaycox et al, 109 Clarke et al, 107 Stice et al, 110 and Garber et al 111 all indicate that the risk of major depression can be reduced in adolescents with subthreshold depression, particularly in the context of a family history of depression. In the case of BD, a small number of retrospective and prospective studies have shown that, while there are some hints of early specificity, these are weak, and it is not possible to differentiate symptomatic young people with emerging BD from those who remit or progress to other syndromal outcomes.
In a recent presentation of the clinical staging model for intervention in depressive disorders, Hetrick et al 108 suggest that simple and effective treatment approaches such as psychoeducation, self-help and e-health, physical activity and exercise therapies, and related behavioural approaches may be appropriate for the earlier stages of depressive disorders. Further intervention studies informed by the clinical staging model are required to test whether such interventions prevent people from progressing to later stages of depressive disorders.
Conclusion
A scientific theory is declared invalid only if an alternate candidate is available to take its place. 112, p 77 Current diagnostic categories in psychiatry impede progress in understanding illness progression and identifying the most effective intervention strategies. Our nosology was created during the age of steam and even the best attempts to tinker with it can do little more than produce a better steam engine. Our current nosology is manifestly invalid, yet we are struggling, as Kuhn's 112 insight shows, to move beyond it through lack of a more valid alternative. Clinical staging may not be the solution to this paralysis; however, it may be able to deliver greater clinical utility in the targeting and evaluation of intervention strategies, and provide a framework for understanding illness progression, including organizing the explosion of biological research findings, thus lighting the path to a more valid nosology.
The staging model suggests the possibility of so-called lumping at the macro level; for example, merging psychoses and mood disorders at the earliest phase, then splitting or subtyping at later stages. Mania, deficit schizophrenia, and tenacious (persistent or chronically relapsing) depression may be among the more distal target syndromes that emerge from this undifferentiated early stage of disorder. There may be a range of other outcomes, including, very commonly, remission and recovery. The challenge remains to map clinical and biological markers across the stages, to define points at which diagnostic specificity and specific predictive factors can be identified, and to refine the most effective intervention strategies for each stage.
Résumé : La starification clinique : une nouvelle stratégie heuristique et pratique pour la recherche et de meilleurs résultats de santé et de fonctionnement social pour les personnes souffrant de troubles psychotiques et de troubles de l'humeur connexes
La plupart des maladies mentales apparaissent à l'adolescence et au début de l'âge adulte, ainsi qu'une détresse associée considérable et un déclin fonctionnel qui se manifestent durant cette phase de développement cruciale. Notre système diagnostique actuel manque de validité thérapeutique, particulièrement aux premières phases des troubles mentaux, quand les symptômes sont encore naissants et qu'ils s'intensifient, et qu'ils ne sont pas encore suffisamment stabilisés pour satisfaire aux critères syndromaux existants. Bien que cela soit en partie attribuable à la difficulté de distinguer les changements transitoires développementaux ou normatifs des premiers symptômes d'une maladie mentale persistante et incapacitante, ces facteurs ont contribué à un mouvement croissant pour la réforme de notre système diagnostique actuel afin de mieux éclairer le choix d'une stratégie thérapeutique, particulièrement aux premières phases d'une maladie mentale. Le modèle de starification clinique, qui définit non seulement l'ampleur de la progression d'un trouble à un point particulier dans le temps mais aussi là où se situe une personne présentement sur le continuum du cours d'une maladie, est particulièrement utile en ce qu'il différencie le phénomène clinique précoce et modéré de ceux qui accompagnent la progression et la chronicité de la maladie. Cela permettra non seulement aux cliniciens de choisir les traitements pertinents aux premières phases de la maladie, où de telles interventions sont susceptibles d'être plus efficaces et moins nocives que les traitements administrés plus tard au cours de la maladie, mais cela permettra également une intégration plus efficace de nos connaissances rapidement grandissantes des facteurs de vulnérabilité biologique, sociale, et psychologique qui participent au développement de la maladie mentale dans un cadre diagnostique utile.
